US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...
FiercePharma12h
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
BioSpace11h
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
Harnessing AI and data science to discover life-changing medicines at AstraZeneca
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca rises Thursday, outperforms market
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
News Medical on MSN1d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...